Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) released its unaudited interim results for the six months ended 30 June 2026.

Revenue and Profitability • Revenue rose 3.1% year on year to RMB 6.85 billion, while gross profit slipped 4.0% to RMB 3.17 billion. • Gross margin fell to 46.3%, down 3.4 percentage points from 49.7% a year earlier, mainly due to price cuts on generic medical devices, orthopaedic products and flush syringes following volume-based procurement. • Net profit attributable to shareholders declined 23.2% to RMB 774.12 million, equating to an 11.3% net margin. • Excluding extraordinary items and foreign-exchange effects, attributable net profit was RMB 890.44 million, down 11.7%.

Segment Performance • Medical device revenue: RMB 3.36 billion, up 5.4%. • Orthopaedic revenue: RMB 698.23 million, down 4.7%. • Interventional revenue: RMB 1.08 billion, down 1.9%; Argon’s sales were hurt by FX losses despite solid product demand. • Pharma-packaging revenue: RMB 1.25 billion, up 7.5%, driven by double-digit growth in prefilled syringes; flush syringe pricing pressure limited gains. • Blood-management revenue: RMB 454.39 million, flat year on year.

Cash Flow and Balance Sheet • Operating cash inflow reached RMB 1.08 billion; period-end cash and bank balances stood at RMB 7.72 billion. • Net cash fell by RMB 908.93 million during the half-year. • Finance costs were largely stable at RMB 117.06 million. • Gearing ratio improved to 16.7% from 21.2% at year-end 2025.

Dividend Proposal The Board proposed an interim dividend of RMB 0.0854 per share, 12% lower than the prior-year interim payout of RMB 0.0969, subject to shareholder approval at an extraordinary general meeting scheduled for 16 October 2026.

Capital Expenditure and Investments • RMB 336.59 million was invested in property, plant and equipment to expand medical consumables capacity. • Progress continued on new production lines for prefilled syringes and auto-injectors (planned investment: RMB 200 million) and on upgrading single-use and orthopaedic consumables equipment (planned investment: RMB 400 million). • The Group has committed RMB 308 million to the Songyuan Healthcare Industry Fund and made other strategic investments, including acquiring a 55% stake in Suzhou Jiesbyer Medical Technology for RMB 83.03 million.

Post-Period Event On 10 August 2026 the Shanghai Stock Exchange’s Mergers and Acquisitions Restructuring Review Committee approved Weigao Blood Purification’s acquisition of 100% of WEGO Prefills from WEIGAO GROUP and two minority partners for RMB 8.51 billion, to be settled via the issue of 271.998 million new Weigao Blood Purification shares. Completion remains subject to China Securities Regulatory Commission registration.

Share Repurchases Between January and June 2026 the Company repurchased 29.00 million H shares on the Hong Kong Stock Exchange for HKD 121.64 million. An additional 2.43 million H shares were bought in July 2026 for HKD 7.95 million. All repurchased shares are held as treasury shares.

Corporate Governance WEIGAO GROUP stated it complied with all provisions of the Corporate Governance Code during the review period. The audit committee has reviewed the unaudited interim financial statements.

Outlook Management signalled ongoing focus on product-mix optimisation, R&D investment and globalisation, while acknowledging continued pricing pressure from China’s volume-based procurement and exchange-rate volatility.